AKT1 and cancer: Direct antitumour effects of mTORC1 inhibitors may require specific biological conditions including the activation of the PI3K/AKT/mTORC1 signalling as well as functional apoptotic pathways, and the circumstances that render cancer cells are highly vulnerable to rapalogues (Faivre et al, 2006a).